The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Lapatinib for Advanced or Metastatic Breast Cancer
Open accessAbstract
Lapatinib is a potent reversible and selective inhibitor of the tyrosine kinase domains of epidermal growth factor receptor and human epidermal growth factor receptor (HER)-2 that exerts its action by competitive binding to the intracellular ATP-binding site of the receptor. It is registered for the treatment of advanced or metastatic HER-2+ breast cancer in combination with capecitabine and for hormone receptor–positive breast cancer in combination with an aromatase inhibitor. Lapatinib administered orally once daily is moderately to well tolerated, with rash and gastrointestinal adverse events as the main toxicities. In studies on the efficacy of lapatinib, direct comparisons between lapatinib and trastuzumab are lacking. Results of ongoing randomized phase III studies with lapatinib or trastuzumab in combination with taxanes as first-line agents for metastatic breast cancer as well as in the neoadjuvant and adjuvant settings are awaited.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Lapatinib is a highly selective EGFR, ERBB2 and ERBB4 inhibitor that is currently FDA-approved for the treatment of a variety of malignancies (59).”
From The drug efflux pump MDR1 promotes intrinsic and acquired resistance to PROTACs in cancer cells (2022) · cites this paper as [59]
Citations
Cites
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer
Geyer, C. E., Forster, J. K., Lindquist, D. L., Chan, S. Y. T., Romieu, C. G., Pieńkowski, T., Jagiełło-Gruszfeld, A., Crown, J. P., Chan, A., Kaufman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa064320 · Cited by 3,458
A Unique Structure for Epidermal Growth Factor Receptor Bound to GW572016 (Lapatinib)
Wood, E. R., Truesdale, A. T., McDonald, O. B., Yuan, D. Y., Hassell, A. M., Dickerson, S. H., Ellis, B., Pennisi, C., Horne, E., Lackey, K. E., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1168 · Cited by 1,125
Johnston, S. R. D., Pippen, J., Pivot, X. B., Lichinitser, M., Sadeghi, S., Dieras, V. C., Gómez, H., Romieu, G., Manikhas, A., Kennedy, M. J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.3734 · Cited by 1,023
Blackwell, K., Burstein, H. J., Storniolo, A. M., Rugo, H. S., Sledge, G. W., Koehler, M. T., Ellis, C. E., Casey, M., Vukelja, S. J., Bischoff, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.4437 · Cited by 940
Cameron, D., Casey, M., Press, M. F., Lindquist, D. L., Pieńkowski, T., Romieu, C. G., Chan, S. Y. T., Jagiełło-Gruszfeld, A., Kaufman, B., Crown, J. P., et al. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9885-0 · Cited by 795
von Minckwitz, G., du Bois, A., Schmidt, M., Maass, N., Čufer, T., de Jongh, F. E., Maartense, E., Zielinski, C. C., Kaufmann, M., Bauer, W., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.6618 · Cited by 674
Xia, W., Mullin, R. J., Keith, B. R., Liu, L.-H., Ma, H., Rusnak, D. W., Owens, G., Alligood, K. J., & Spector, N. L. (2002) · Oncogene · doi:10.1038/sj.onc.1205794 · Cited by 671
Burris, H. A., Hurwitz, H. I., Dees, E. C., Dowlati, A., Blackwell, K., O’Neil, B. H., Marcom, P. K., Ellis, M. J., Overmoyer, B. A., Jones, S. F., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.16.584 · Cited by 619
Leo, A. D., Gómez, H., Aziz, Z., Zvirbule, Z., Bines, J., Arbushites, M. C., Guerrera, S., Koehler, M. T., Oliva, C., Stein, S. H., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.2578 · Cited by 417
Flagged first, then by citations
Research works printed but not linked: 13
- European Medicines Agency, Tyverb® Summary of Product Characteristics
- U.S. Food and Drug Administration, Tykerb® Approval Letter 13–3-2007
- U.S. Food and Drug Administration, Tykerb® Approval Letter 29–01-2010
- U.S. Food and Drug Administration, Tykerb®. Clinical Pharmacology and Biopharmaceutics NDA review
- U.S. Food and Drug Administration Center for Drug Evaluation and Research, Medical Review Tykerb®. 6–3-2007
- European Medicines Agency, Assessment Report for Tyverb®. Procedure No. EMEA H/C/795, 2008
- National Institute for Health and Clinical Excellence (NICE), Final Appraisal Determination: Lapatinib for the Treatment of Women With Previously Treated Advanced or Metastatic Breast Cancer
- National Institute for Health and Clinical Excellence (NICE), Liverpool Review and Implementation Group. Lapatinib and Trastuzumab in Combination With an Aromatase Inhibitor for the First-Line Treatment of Metastatic Hormone Receptor Positive Breast Cancer Which Overexpresses HER-2
- CFH-Rapport 11/34: Lapatinib (Tyverb®) in Combinatie met een Aromataseremmer
- ClinicalTrials.gov ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2–06/N063D
- Tykerb Evaluation After Chemotherapy (TEACH): Lapatinib Versus Placebo In Women With Early-Stage Breast Cancer
- Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study
- Wikipedia, Bestand:Lapatinib.svg
Cited by
Sorted by citations
Items 101–114 of 114
Resistance of HER2-expressing ovarian cancer to trastuzumab and mechanisms of overcoming resistance
McWhorter, R., Libra, M., & Bonavida, B. (2024) · Elsevier eBooks · doi:10.1016/b978-0-12-816408-2.00014-2
Ashtekar, K. D., Lemmon, M. A., & Tsutsui, Y. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.10.14.618277
HER2-positive (HER2+) & HER2-negative (HER2−) targeted therapies
Bambal, V., Rathore, S. S. S., Jenita⃰, J. J. L., Paul, P., Singh, P. K., & Kenchappa, V. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33349-1.00006-5
Sarkar, P., Ahuja, S., & Lazar, I. M. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.10.31.685975
Bis‐Furans: A Sustainable Source of Diverse Molecular Architectures
Cardoso, A. L., Paixão, J. A., & Melo, T. M. V. D. P. E. (2026) · European Journal of Organic Chemistry · doi:10.1002/ejoc.202501191
Koźlak, M. (2019) · theses.fr (ABES) · doi:10.70675/0fd942ebz4198z4499za7eazb6a4014d0e09
Yao, P. (2026) · Highlights in Science Engineering and Technology · doi:10.54097/rj7r3r25
Scaffold-free 3D-cell co-culture model system for the study of metastatic cancer in the brain TME
Sarkar, P., Ahuja, S., & Lazar, I. M. (2026) · PLoS ONE · doi:10.1371/journal.pone.0349061
Aspirin enhances the anti-tumour activity of lapatinib in HER2-positive breast cancer
Luo, H., Yuan, P., Guo, K., Chen, J., Xu, J., Jiang, Y., Wang, C., Liu, J., Wang, B., & Zhu, X. (2026) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2026.179132
Yoga, I. M. B. K., Irmasari, I., Widyardhita, M. H., Maharani, D., Widayanti, W. R., Amalia, A., Ningsih, S. R., Saputra, B. W., Haidar, I., Putri, D. D. P., et al. (2026) · Phytomedicine · doi:10.1016/j.phymed.2026.158698
VanWert, A. L., Grant, P. A., Kumari, N., & Bommareddy, A. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-44037-3.00311-0
Hussan, K. P. S., Oki, Y., Yokose, H., Furuhata, K., Chen, L., Shinha, K., Ito, T., Okamura, Y., Kimura, H., Kita, R., et al. (2026) · Materials Today Communications · doi:10.1016/j.mtcomm.2026.116275
Metadata
- Authors
- Opdam, F. L., Guchelaar, H.-J., Beijnen, J. H., & Schellens, J. H. M.
- Affiliations
- Leiden University (NL)
- Utrecht University (NL)
- Corresponding author
- Schellens, Jan H.M.
- Venue
- The Oncologist
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-04-01
- Volume
- 17
- Issue
- 4
- Pages
- 536-542
- ISSN
- 1083-7159 (ISSN-L)
- 1549-490X
- PMC
- PMC3336826
- OpenAlex
- W2169052701
- Cited by
- 113
- References
- 33
- Citations by year
- 2026: 8 · 2025: 10 · 2024: 23 · 2023: 9 · 2022: 12 · 2021: 12 · 2020: 4 · 2019: 6 · 2018: 5 · 2017: 3 · 2016: 2 · 2015: 4 · 2014: 5 · 2013: 8 · 2012: 2
- FWCI
- 0.66
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- The Oncologist (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Leiden Repository (Leiden University) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Keywords
- lapatinib, HER2-positive breast cancer, metastatic breast cancer, tyrosine kinase inhibitors, EGFR, HER2, capecitabine, aromatase inhibitors, hormone receptor-positive breast cancer, trastuzumab, drug toxicity, rash, gastrointestinal adverse effects, taxanes
- MeSH terms
- Lapatinib, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Female, Humans, Neoplasm Metastasis, Quinazolines, Protein Kinase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
